Please assess the completion status of the following clinical trial:

Trial Title: Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Patients already treated with Insuplant 400 IU/ml via a Medtronic Implantable System 2007~2. Glycosylated hemoglobin ≤9.0%~3. Patient showing a percentage of error at refill equal or below 20%~4. Patient undergoing NaOH rinse procedure of at least 10 minutes period with or without flush Or Patient being re-implanted with a new pump (first fill with insulin)~5. Signed informed consent form prior to enrolment~Exclusion criteria:~1. Pump life time \> 6 years~2. Pump battery voltage \< 2.6 volts~3. Pregnancy or childbearing potential without a medically approved form of birth control~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insuman Implantable (Type: EXPERIMENTAL): Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
- Insuplant (Type: ACTIVE_COMPARATOR): Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).